The price and formal purchasing channels of LARTRUVO

Olaratumab (LARTRUVO) is not available in China, and patients need to purchase it through formal overseas channels. Its intravenous solution (10mg/ml) has a market price of approximately 984 US dollars per bottle of 19ml. This drug is mainly used to treat advanced soft tissue sarcoma (STS). Due to its high price, patients and medical institutions often need to consider the balance between drug cost and treatment effectiveness, especially for long-term treatment or repeated use. LartruvoThe cost will be affected by several factors, such as regional differences, drug supply channels, and whether it is covered by insurance plans. In some countries, patients may require additional financial support or assistance programs to cover this cost. Despite its higher price, Lartruvo still offers new treatment hope and options for patients who cannot achieve effective control with traditional treatments.

Olaratumab (Olaratumab), trade nameLARTRUVO, is a humanized monoclonal antibody mainly used to treat advanced soft tissue sarcoma (STS). It inhibits tumor cell growth and angiogenesis by targeting platelet-derived growth factor receptor α (PDGFR-α). LARTRUVO can be used in combination with traditional chemotherapy drugs such as docetaxel, and the effect is more significant than a single chemotherapy drug.

In clinical application, LARTRUVO has shown significant efficacy, especially for patients with advanced soft tissue sarcoma who are ineffective with traditional chemotherapy. According to multiple clinical trials, patients treated with LARTRUVO combined with chemotherapy have significantly improved overall survival and progression-free survival compared with patients treated with chemotherapy alone. LARTRUVOThe side effects include fatigue, nausea, anemia, leukopenia, etc. The overall safety is relatively controllable, but it still needs to be used under the guidance of a doctor.

AlthoughLARTRUVO is more expensive, it provides an effective treatment option for patients with advanced soft tissue sarcoma, especially those who are ineffective or resistant to conventional treatments. Therefore, LARTRUVO is considered an effective and promising drug.

Reference materials:https://www.drugs.com/cdi/olaratumab.html